🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOral GLP-1 AgonistsOral GLP-1 pipeline overview — all agents in development Page 5

Oral GLP-1 pipeline overview — all agents in development

TrialTracker_MD Mon, Feb 26, 2024 at 4:00 PM 291 replies 50,237 viewsPage 5 of 20
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Mar 1, 2024 at 2:28 AM#21

Following on from PharmD_Rodriguez — and this may be the naive question:

How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?

38 11pam_stl, wei_SG, cory_ATX and 35 others
Reply Quote Save Share Report
A1cHero_PHX
Member
523
2,678
Jul 2024
Phoenix, AZ
Mar 2, 2024 at 2:06 AM#22
cory_ATX said:
The useful move here is to separate what is established from what is widely repeated.

I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.

39 12KarenAZ_mom, zoe_NC, Dr.ObesityLA and 36 others
Reply Quote Save Share Report
NurseLeah_Nash
Member
278
1,234
Sep 2024
Nashville, TN
Mar 3, 2024 at 1:44 AM#23
cory_ATX said:
The useful move here is to separate what is established from what is widely repeated.

That is right, and it stops being right at the edges. The general case is well behaved; the interesting cases in this thread are all at the boundary where the general case breaks.

Happy to go further on any of that.

40 13PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 37 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
wei_SG
Member
234
890
Nov 2024
Singapore, SG
Mar 4, 2024 at 1:21 AM#24
cory_ATX said:
The useful move here is to separate what is established from what is widely repeated.

Genuinely useful, thank you. I had the facts and not the framework. I will report back once I have actually tried it.

Last edited: Mar 4, 2024 at 2:21 AM
41 14RetaRick_CA, JenPlateau, SallyK_inj and 38 others
Reply Quote Save Share Report
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Mar 5, 2024 at 12:57 AM#25

Adding the clinical framing, because it changes how the question reads. Whatever the answer turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, and invite the correction. That is slower than asserting, and it is the only version that survives being wrong.

I would rather be corrected than agreed with, if it comes to it.

42 15claudia_zurich, nancy_portland, rick_sfbay and 39 others
Reply Quote Save Share Report
13456720

Similar Threads

Orforglipron Phase 3 ATTAIN-1 topline — oral non-peptide GLP-116 replies
Oral semaglutide 50mg (Rybelsus HD) — OASIS program results12 replies
Danuglipron BID dosing — Pfizer oral GLP-1 update7 replies
Oral vs injectable GLP-1: bioavailability and efficacy comparison5 replies
Orforglipron food interaction profile — no fasting requirement15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register